The association between carbamazepine and valproate and adverse cutaneous drug reactions in patients with bipolar disorder: A nested matched case-control study

Journal of Clinical Psychopharmacology

Volumn 28, Issue 5, 2008, Pages 509-517

  Gau, Susan Shur Fen ^a,b,c,d   Chao, Pei Fong ^a,d   Lin, Yu Ju ^a   Chang, Ching Jui ^b,e,f   Gau, Churn Shiouh ^d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b University College of Medicine   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e CATHAY GENERAL HOSPITAL   (Taiwan)

^f FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; ALLOPURINOL; AMINOPENICILLIN; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CEPHALOSPORIN; CHLORMEZANONE; FENAMIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; LAMOTRIGINE; MACROLIDE; MEFENAMIC ACID; OXICAM DERIVATIVE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PROPIONIC ACID; QUINOLONE DERIVATIVE; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; TETRACYCLINE DERIVATIVE; VALPROIC ACID; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR DISORDER; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DATA BASE; DRUG EXPOSURE; ERYTHEMA MULTIFORME; FEMALE; HOSPITAL PATIENT; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STEVENS JOHNSON SYNDROME; TAIWAN; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; DRUG INTERACTION; FACTUAL DATABASE; MIDDLE AGED;

ACETAMINOPHEN; ADULT; ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DRUG ERUPTIONS; DRUG INTERACTIONS; EPIDERMAL NECROLYSIS, TOXIC; ERYTHEMA MULTIFORME; FEMALE; HUMANS; MALE; MIDDLE AGED; STEVENS-JOHNSON SYNDROME; VALPROIC ACID;

EID: 58149139985     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181845610     Document Type: Article

References (47)

1. Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions. A report from the Boston collaborative drug surveillance program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986;24:3358-3363.
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N EnglJMed. 1994;331:1272-1285.
3. Farthing P, Bagan JV Scully C. Mucosal disease series. Number IV Erythema multiforme. Oral Dis. 2005;11:261-267.
4. Wolkenstein P, Revuz J. Drug-induced severe skin reactions. Incidence, management and prevention. Drug Saf. 1995;13:56-68.
5. Assier H, Bastuji-Garin S, Revuz J, et al. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol. 1995;131:539-543.
6. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019-1024.
7. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43-47.
8. Schopf E, Stuhmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127:839-842.
9. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol. 1990;126:37-12.
10. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
11. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. JInvestDermatol. 1994;102:28S-30S.
12. Duncan KO, Tigelaar RE, Bolognia JL. Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital. JAm Acad Dermatol. 1999;40:493-496.
13. Fournier S, Bastuji-Garin S, Mentec H, et al. Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. Eur JClin Microbiol Infect Dis. 1995;14:558-559.
14. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int. 2007;56:419-425.
15. Villada G, Roujeau JC, Cordonnier C, et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol. 1990;23:870-875.
16. Lin MS, Dai YS, Pwu RF, et al. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Intern Med J. 2005;35:188-190.
17. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study group of the international case control study on severe cutaneous adverse reactions. Lancet. 1999;353:2190-2194.
18. Warnock JK, Morris DW. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol. 2003;4:21-30.
19. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burns centre: a 6- year review. Burns. 1996;22:275-278.
20. Kamaliah MD, Zainal D, Mokhtar N, et al. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in northeastern Malaysia. Int J Dermatol. 1998;37:520-523.
21. Li TH, Chan YC, Sun CC. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis antecedent drug exposures in 99 hospitalized patients. Dematol Sinica. 1996;14:119-125.
22. Devi K, George S, Criton S, et al. Carbamazepine-the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian JDermatol Venereol Leprol. 2005;71:325-328.
23. The National Reporting System of Adverse Drug Reactions in Taiwan. Available at: http://adr.doh.gov.tw/default.asp. Accessed on May 14,2008.
24. Friedmann PS, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol. 1994;130:598-604.
25. Arroyo S, Sander JW. Carbamazepine in comparative trials: pharmacokineticcharacteristics too oftenforgotten. Neurology. 1999;53:1170-1174.
26. Vicente B, Kohn R, Rioseco P, et al. Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am J Psychiatry. 2006;163:1362-1370.
27. Grant BF, Stinson FS, Hasin DS, et al. Prevalence, correlates, and comorbidity of bipolar I disorder and axis I and II disorders: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry. 2005;66:1205-1215.
28. Chien IC, Chou YJ, Lin CH, et al. Prevalence of psychiatric disorders among national health insurance enrollees in Taiwan. Psychiatr Serv.2004;55:691-697.
29. ten Have M, Vollebergh W, Bijl R, et al. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord. 2002;68:203-213.
30. Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am JPsychiatry. 2002;159:1005-1010.
31. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007;58:85-91.
32. Chien IC, Bih SH, Chou YJ, et al. Trends in the use of psychotropic drugs in Taiwan: a population-based national health insurance study, 1997-2004. Psychiatr Serv. 2007;58:554-557.
33. Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord. 2000;2:120-130.
34. Chang CJ, Chiou SY, Chang SY, et al. Psychiatric Inpatient Medical Claim Dataset (in Chinese); 2004. http://www.nhri.org.tw/nhird/file-talk/ psy-document.pdf. Accessed on May 14, 2008.
35. Fawcett RG. Erythema multiforme major in a patient treated with carbamazepine. J Clin Psychiatry. 1987;48:416-417.
36. Askmark H, Wiholm BE. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol Scand. 1990;81:131-140.
37. Konishi T, Naganuma Y, Hongo K, et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr. 1993;152:605-608.
38. Li LF, Ma C. Epidemiological study of severe cutaneous adverse drug reactions in a city district of China. Clin Exp Dermatol. 2006;31:642-647.
39. Leenutaphong V, Sivayathorn A, Suthipinittharm P, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol. 1993;32:428-431.
40. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:86.
41. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128:35-44.
42. Tsai SJ, Chen YS. Valproic acid-induced Stevens-Johnson syndrome. J Clin Psychopharmacol. 1998;18:420.
43. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49:542-546.
44. Hilas O, Charneski L. Lamotrigine-induced Stevens-Johnson syndrome. Am J Health Syst Pharm. 2007;64:273-275.
45. Bellantuono C, Barraco A, Rossi A, et al. The management of bipolar mania: a national survey of baseline data from the EMBLEM study in Italy. BMC Psychiatry. 2007;7:33.
46. Ghaemi SN, Hsu DJ, Thase ME, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv. 2006;57:660-665.
47. Huang CW, Tsai JJ, Lai ML. Lamotrigine-related skin rashes in adults. Kaohsiung J Med Sci. 2002;18:566-572.